Buy & Sell Appian Corp (APPN) – Appian Corp Price Today
Aura AI Summary
Key Stats
- $1.82BMarket Cap
- TechnologySector
- -29.54%3M Drawdown
- $1.90BEnterprise Value
- -Dividend Yield
- 18 daysTypical Hold Time
Appian Corp (APPN) is currently valued at a market capitalization of $1.82B, with an enterprise value of $1.90B. Over the past 52 weeks, Appian Corp has traded between a low of $18.72 and a high of $45.64, highlighting its annual price range. Over the past three months, Appian Corp has recorded a drawdown of -29.54%, reflecting recent price volatility. On average, investors hold Appian Corp for approximately 18 days, indicating typical investor behavior on the platform.
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Most Recent News
OpenAI plans major upgrade to boost ChatGPT amid IPO and competition with Anthropic.
OpenAI is preparing its biggest upgrade yet, transforming ChatGPT into a superapp with multiple tools like coding and AI agents to better compete with Anthropic. This move aims to attract more corporate clients and increase revenue as OpenAI readies ...
Repatha cuts first major cardiovascular event risk by 29% in high-risk diabetes patients, new trial data show
New Phase 3 VESALIUS-CV trial data reveal that Repatha (evolocumab), added to statins, reduces the risk of first major cardiovascular events by 29% in patients with high-risk diabetes and elevated LDL cholesterol. The study involved 6,002 patients wi...
Investors may claim losses after ADMA Biologics shares fell 16.6% amid fraud allegations.
Rosen Law Firm is investigating securities claims against ADMA Biologics following allegations that the company misled investors by inflating revenue through channel stuffing. The stock dropped 16.6% on March 24, 2026, after a short seller report by ...
